Literature DB >> 16652319

Web resources for HIV type 1 genotypic-resistance test interpretation.

Tommy F Liu1, Robert W Shafer.   

Abstract

Interpreting the results of plasma human immunodeficiency virus type 1 (HIV-1) genotypic drug-resistance tests is one of the most difficult tasks facing clinicians caring for HIV-1-infected patients. There are many drug-resistance mutations, and they arise in complex patterns that cause varying levels of drug resistance. In addition, HIV-1 exists in vivo as a virus population containing many genomic variants. Genotypic-resistance testing detects the drug-resistance mutations present in the most common plasma virus variants but may not detect drug-resistance mutations present in minor virus variants. Therefore, interpretation systems are necessary to determine the phenotypic and clinical significance of drug-resistance mutations found in a patient's plasma virus population. We describe the scientific principles of HIV-1 genotypic-resistance test interpretation and the most commonly used Web-based resources for clinicians ordering genotypic drug-resistance tests.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16652319      PMCID: PMC2547473          DOI: 10.1086/503914

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  46 in total

1.  The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team.

Authors:  C Katlama; B Clotet; A Plettenberg; J Jost; K Arasteh; E Bernasconi; V Jeantils; A Cutrell; C Stone; M Ait-Khaled; S Purdon
Journal:  AIDS       Date:  2000-05-05       Impact factor: 4.177

2.  Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype.

Authors:  Niko Beerenwinkel; Barbara Schmidt; Hauke Walter; Rolf Kaiser; Thomas Lengauer; Daniel Hoffmann; Klaus Korn; Joachim Selbig
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

3.  A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients.

Authors:  Kristel Van Laethem; Andrea De Luca; Andrea Antinori; Antonella Cingolani; Carlo Federico Perna; Anne-Mieke Vandamme
Journal:  Antivir Ther       Date:  2002-06

4.  Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.

Authors:  Samir Vora; Anne-Geneviève Marcelin; Huldrych F Günthard; Philippe Flandre; Hans H Hirsch; Bernard Masquelier; Annelies Zinkernagel; Gilles Peytavin; Vincent Calvez; Luc Perrin; Sabine Yerly
Journal:  AIDS       Date:  2006-01-02       Impact factor: 4.177

5.  Clinical utility of HIV-1 genotyping and expert advice: the Havana trial.

Authors:  Cristina Tural; Lidia Ruiz; Christopher Holtzer; Jonathan Schapiro; Pompeyo Viciana; Juan González; Pere Domingo; Charles Boucher; C Rey-Joly; Bonaventura Clotet
Journal:  AIDS       Date:  2002-01-25       Impact factor: 4.177

6.  A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.

Authors:  Bluma Brenner; Dan Turner; Maureen Oliveira; Daniela Moisi; Mervi Detorio; Mauricio Carobene; Richard G Marlink; Jonathan Schapiro; Michel Roger; Mark A Wainberg
Journal:  AIDS       Date:  2003-01-03       Impact factor: 4.177

7.  Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population.

Authors:  M J Gonzales; R N Machekano; R W Shafer
Journal:  J Infect Dis       Date:  2001-09-10       Impact factor: 5.226

8.  Comparison of virtual phenotype and HIV-SEQ program (Stanford) interpretation for predicting drug resistance of HIV strains.

Authors:  E Puchhammer-Stöckl; C Steininger; E Geringer; F X Heinz
Journal:  HIV Med       Date:  2002-07       Impact factor: 3.180

9.  Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.

Authors:  Bernard Masquelier; Dominique Breilh; Didier Neau; Sylvie Lawson-Ayayi; Valérie Lavignolle; Jean-Marie Ragnaud; Michel Dupon; Philippe Morlat; F Dabis; H Fleury
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

10.  Human immunodeficiency virus reverse transcriptase and protease sequence database.

Authors:  Soo-Yon Rhee; Matthew J Gonzales; Rami Kantor; Bradley J Betts; Jaideep Ravela; Robert W Shafer
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

View more
  269 in total

1.  Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India.

Authors:  Maria L Ekstrand; Anita Shet; Sara Chandy; Girija Singh; Ranjani Shamsundar; Vidya Madhavan; Shanmugam Saravanan; Elsa Heylen; Nagalingeswaran Kumarasamy
Journal:  Int Health       Date:  2011-03       Impact factor: 2.473

2.  Unusual insertion and deletion at codon 67 and 69 of HIV type 1 subtype C reverse transcriptase among first-line highly active antiretroviral treatment-failing South Indian patients: association with other resistance mutations.

Authors:  Shanmugam Saravanan; Vidya Madhavan; Rami Kantor; Sathasivam Sivamalar; Selvamurthi Gomathi; Sunil S Solomon; Nagalingeswaran Kumarasamy; Davey M Smith; Robert T Schooley; Suniti Solomon; Pachamuthu Balakrishnan
Journal:  AIDS Res Hum Retroviruses       Date:  2012-05-21       Impact factor: 2.205

3.  Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool.

Authors:  Conan K Woods; Chanson J Brumme; Tommy F Liu; Celia K S Chui; Anna L Chu; Brian Wynhoven; Tom A Hall; Christina Trevino; Robert W Shafer; P Richard Harrigan
Journal:  J Clin Microbiol       Date:  2012-03-07       Impact factor: 5.948

Review 4.  The HIVdb system for HIV-1 genotypic resistance interpretation.

Authors:  Michele W Tang; Tommy F Liu; Robert W Shafer
Journal:  Intervirology       Date:  2012-01-24       Impact factor: 1.763

5.  A retrospective survey of HIV drug resistance among patients 1 year after initiation of antiretroviral therapy at 4 clinics in Malawi.

Authors:  Nellie Wadonda-Kabondo; Bethany L Hedt; Joep J van Oosterhout; Kundai Moyo; Eddie Limbambala; George Bello; Ben Chilima; Erik Schouten; Anthony Harries; Moses Massaquoi; Carol Porter; Ralf Weigel; Mina Hosseinipour; John Aberle-Grasse; Michael R Jordan; Storn Kabuluzi; Diane E Bennett
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

6.  Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy.

Authors:  B Chaplin; G Eisen; J Idoko; D Onwujekwe; E Idigbe; I Adewole; W Gashau; S Meloni; A D Sarr; J L Sankalé; E Ekong; R L Murphy; P Kanki
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-21       Impact factor: 2.205

7.  HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels.

Authors:  Michael R Jordan; Julie Winsett; Aileen Tiro; Vuth Bau; Rony S Berbara; Christopher Rowley; Nobel Bellosillo; Christine Wanke; Eoin P Coakley
Journal:  World J AIDS       Date:  2013-06

8.  Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children.

Authors:  Theodore D Ruel; Moses R Kamya; Pelin Li; William Pasutti; Edwin D Charlebois; Teri Liegler; Grant Dorsey; Philip J Rosenthal; Diane V Havlir; Joseph K Wong; Jane Achan
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

9.  In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors.

Authors:  Hao Wu; Xiao-Min Zhang; Hao-Jie Zhang; Qiwei Zhang; Zhiwei Chen; Jian-Dong Huang; Shui-Shan Lee; Bo-Jian Zheng
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01-08       Impact factor: 2.205

Review 10.  Review of HIV antiretroviral drug resistance.

Authors:  Tempe K Chen; Grace M Aldrovandi
Journal:  Pediatr Infect Dis J       Date:  2008-08       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.